| 000 -LEADER |
|---|
| fixed length control field |
03388nam a22004455i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20140310150235.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
110920s2012 xxu| s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9781461406136 |
|
978-1-4614-0613-6 |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
RC261-271 |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
614.5999 |
| Edition number |
23 |
| 264 #1 - |
|---|
| -- |
New York, NY : |
| -- |
Springer New York, |
| -- |
2012. |
| 912 ## - |
|---|
| -- |
ZDB-2-SBL |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Terabe, Masaki. |
| Relator term |
editor. |
| 245 10 - IMMEDIATE SOURCE OF ACQUISITION NOTE |
|---|
| Title |
Natural Killer T cells |
| Medium |
[electronic resource] : |
| Remainder of title |
Balancing the Regulation of Tumor Immunity / |
| Statement of responsibility, etc |
edited by Masaki Terabe, Jay A. Berzofsky. |
| 250 ## - EDITION STATEMENT |
|---|
| Edition statement |
1. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
XII, 208 p. |
| Other physical details |
online resource. |
| 440 1# - SERIES STATEMENT/ADDED ENTRY--TITLE |
|---|
| Title |
Cancer Drug Discovery and Development |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Preface.- Introduction: Mechanisms of NKT cell-mediated adjuvant activity and function of iPS-derived NKT cells -- Structure and Recognition of Antigens for Invariant NKT Cells -- Invariant NKT cell-based vaccine strategies -- Immune regulation of tumor immunity by NKT cells -- The Regulation of CD1d+ and CD1d- tumors by NKT Cells -- DC-based immunotherapy targeting NKT cells -- Therapeutic Approaches Utilising NKT Cells -- NKT Cells of Cancer Patients & How Models can Inform Therapeutic Plans -- Understanding the role of Natural Killer T (NKT) cells in hematologic malignancies: progress and challenges -- Clinical trials with α-galactosylceramide (KRN7000) in advanced cancer -- Clinical trials of invariant Natural Killer T cell-based immunotherapy for cancer -- Index. . |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc |
Natural killer T (NKT) cells are CD1d-restricted T cells that respond to lipid, not protein, antigens presented by CD1d, which is a non-classical MHC class I-like molecule. This relatively small but pivotal T cell population bridges the gap between innate and adaptive immunity by rapidly produce large amounts of many kinds of cytokines and by providing the T cell arm of the adaptive immune system a mechanism to detect lipid antigens. NKT cells also have both regulatory and effector functions and have been shown to play critical roles in the regulation of immune responses in many disease settings including cancer. Stimulating the protective functions of NKT cells while inhibiting the negative regulatory activity shows promise for the therapy of cancer and several approaches are in clinical trials. This book reviews what we have learned about NKT cells during last two decades through functional studies in the context of tumor immunology, including clinical trials of NKT cell targeted therapy. This knowledge should also be informative to understand the role of this underappreciated T cell population in many other fields outside of tumor immunology. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Medicine. |
|
|---|
| Topical term or geographic name as entry element |
Oncology. |
|
|---|
| Topical term or geographic name as entry element |
Toxicology. |
|
|---|
| Topical term or geographic name as entry element |
Biomedicine. |
|
|---|
| Topical term or geographic name as entry element |
Cancer Research. |
|
|---|
| Topical term or geographic name as entry element |
Pharmacology/Toxicology. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Berzofsky, Jay A. |
| Relator term |
editor. |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY |
|---|
| Title |
Springer eBooks |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Display text |
Printed edition: |
| International Standard Book Number |
9781461406129 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
http://dx.doi.org/10.1007/978-1-4614-0613-6 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
|
| Item type |
E-Book |
